Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | PNMT | P11086 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26060350 | 1.00 | TAAR1 (0.57) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL3278227 | 0.85 | ALOX15 (0.61) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL26055335 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL30119610 | 0.83 | TAAR1 (0.57) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL25533453 | 0.83 | ALOX15 (0.49) | TAAR1SLC6A2SLC6A3SLC6A4ALOX15 | |
| Hydrochloric Acid SCHEMBL31070400 | 0.82 | TAAR1 (0.55) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL8733806 | 0.80 | ADRB2 (0.54) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL8733813 | 0.80 | ADRB2 (0.54) | TAAR1SLC6A2SLC6A3SLC6A4PNMT | |
| SCHEMBL25533176 | 0.78 | SIGMAR1 (0.46) | TAAR1SLC6A2SLC6A3SLC6A4ALOX15 | |
| SCHEMBL25533321 | 0.78 | SIGMAR1 (0.46) | TAAR1SLC6A2SLC6A3SLC6A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | SLC6A3, DBH, PNMT | TAAR1 103/4885SLC6A2 10/4885SLC6A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.